NCT02115503 - A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 31, 2019

Study Completion Date

April 30, 2020

Conditions

Renal Transplant Recipients With Anti-HLA Antibodies

Trial Locations (8)

Cornell Medical Center, New York

University of Miami, Miami

Baylor Research Institute, Fort Worth

Houston Methodist Hospital, Houston

University of Colorado, Denver, Aurora

St Vincent's Transplant Research Institute, Los Angeles

University of California Davis Health Systems, Sacramento

Massachusetts General Hospital, Boston